Cortigent

Cortigent

Cortigent emerged from the intellectual property and clinical legacy of Second Sight Medical Products, the entity responsible for the Argus II retinal prosthesis. When Second Sight wound down and subsequently merged with Nano Precision Medical in 2022, the brain-stimulation technology was carved into a separate vehicle. The firm holds an investigational device exemption from the FDA for the Orion Visual Cortical Prosthesis, which uses an electrode array placed on the surface of the brain's visual cortex to generate phosphenes — points of perceived light — in individuals with near-total blindness. This approach addresses a broader patient population than retinal implants because it bypasses the optic nerve, targeting those with glaucoma, diabetic retinopathy, or traumatic eye injury. The firm's single asset is a neurostimulation system in clinical development. An early feasibility study at UCLA and Baylor College of Medicine has demonstrated that Orion recipients can localize objects and identify letters with clinically meaningful accuracy. Cortigent operates as a development-stage medical device company; it does not manage third-party capital, participate in fund commitments, or engage in direct investments beyond the Orion program. Research is funded through a combination of equity raises and grants from the National Institutes of Health. The technology is subject to the same regulatory pathway as other Class III implantable neurological devices, requiring a pivotal trial and premarket approval submission to the FDA before commercialization. Cortigent has historically maintained a lean organizational structure with no disclosed secondary offices. In February 2023, the firm filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering, seeking to raise capital to advance the Orion clinical program through the pivotal trial stage. No updates have followed that filing, and the public offering has not priced. The company's workforce is centered on neuroengineering and clinical regulatory professionals. Cortigent does not disclose operating metrics or headcount. There is no disclosed family-office affiliation or private wealth backing; existing shareholders are institutional accounts and public-market investors from the Second Sight era. Cortigent is structurally a single-asset development company, not a diversified allocator or multi-strategy family office. The unusual mandate — building a brain-computer interface for sight restoration under FDA regulation — sets it apart from technology investment entities that spread risk across a portfolio. Its commercial viability depends entirely on a single device's clinical trial results, creating a binary risk profile unlike the pooled-risk architecture of a family office or venture firm. Succession risk is tied directly to executive retention following the Second Sight transition, and to the firm's ability to fund a lengthy regulatory process without interim revenue.